Doxil/Caefyx

Facts from the Community

From the BioVenturist base

Indication or disease:

Disease Phase of development

Delivery Technology:

Technology involved:

Stage of development:

top ↑

We can tell you that Doxil/Caefyx is a…

If you know more about Doxil/Caefyx, you can add more facts here »

Similar topics in Freebase

  • Epoetin alfa

    Epoetin alfa (rINN) (pronounced /ɛˈpoʊɨtɨn/) is a synthetic form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy. Epoetin is marketed under the trade names Procrit...
  • Ambisome

  • Renagel

  • Muromonab

    Muromonab-CD3 (generic name) is a monoclonal antibody (mAb), also known as Orthoclone OKT3 (Brand name). It is a mouse-derived (murine) monoclonal antibody that specifically binds to the CD3 (T3) protein found on the surface of T cells. Of historical note is that this was the first mAb approved...
  • Abciximab

    Abciximab (previously known as c7E3 Fab), manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus ...
  • Pegfilgrastim

    Pegfilgrastim is a immunostimulator which functions as a PEGylated granulocyte colony-stimulating factor. Amgen manufactures pegfilgrastim under the brand name Neulasta.

You can help improve this topic by adding more facts here

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution